Asset profile
stenoparib
Small molecule
Evidence outlook
Completed readouts not yet graded
This drug has completed mid- or late-stage studies whose evidence has not yet been graded on this platform. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
12 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 12 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Stenoparib: this drug | Phase 2 | Small molecule | — | ||
| Avutometinib | Approved | Small molecule | RAF/MEK, MEK1/2 and RAF (CRAF, BRAF) | ||
| Defactinib | Approved | Small molecule | FAK | ||
| Niraparib | Approved | Small molecule | PARP1/2 | ||
| Relacorilant (Lifyorli) | Approved | Small molecule | Glucocorticoid receptor | ||
| INCB123667 | Phase 3 | Small molecule | — | ||
| Olvimulogene Nanivacirepvec | Phase 3 | Oncolytic Virus | No discrete molecular target | ||
| Rina-S | Phase 3 | Small molecule | Folate receptor alpha (FRα) | ||
| Luveltamab Tazevibulin | Phase 2/3 | Antibody–drug conjugate | — | ||
| Birinapant | Phase 2 | — | — | ||
| COM701 | Phase 1 | Small molecule | — | ||
| IDE-161 | Phase 1 | Small molecule | PARG | ||
| XmAb541 | Phase 1 | Multispecific antibody | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
March 2027 (1)
What to watch
2029 (1)
December 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.